Company Description
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States.
It develops GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine.
In addition, the company offers GEO-MVA-MUC1, a vaccine candidate, which is in preclinical trial for the treatment of solid tumor cancers; GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-EMO1-Z, which is in preclinical trial for the treatment of Ebola Zaire; GEO-EMO1-S, which is in preclinical trial for the treatment of Ebola Sudan; GEO-MM01 treatment for marburg; and GEO-MVA for the treatment of Mpox and small pox.
It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; and the U.S. Department of Defense.
GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.
| Country | United States |
| Founded | 2001 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 19 |
| CEO | David Dodd |
Contact Details
Address: 1955 Lake Park Drive, Suite 380 Smyrna, Georgia 30080 United States | |
| Phone | 678 384 7220 |
| Website | geovax.com |
Stock Details
| Ticker Symbol | GOVX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000832489 |
| CUSIP Number | 373678705 |
| ISIN Number | US3736787058 |
| Employer ID | 87-0455038 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| David Alan Dodd | Chairman, President and Chief Executive Officer |
| Dr. Mark J. Newman Ph.D. | Chief Scientific Officer |
| Dr. Kelly T. McKee Jr., M.D., M.P.H. | Chief Medical Officer |
| Dr. Harriet Latham Robinson Ph.D. | Founder, Chief Scientific Officer Emeritus and Member of Scientific Advisory Board |
| Mark W. Reynolds C.P.A. | Chief Financial Officer and Corporate Secretary |
| Thomas O'Brien | Vice President of Quality Systems and Compliance |
| Jeffrey Welch | Head of Process Development and Manufacturing Operations |
| Dr. John W. Sharkey Ph.D. | Vice President of Business Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 26, 2026 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| May 19, 2026 | 8-K | Current Report |
| May 18, 2026 | DEFR14A | Filing |
| May 15, 2026 | SCHEDULE 13G/A | Filing |
| May 14, 2026 | 8-K | Current Report |
| May 14, 2026 | 10-Q | Quarterly Report |
| May 13, 2026 | SCHEDULE 13G/A | Filing |
| May 8, 2026 | PRER14A | Filing |
| May 7, 2026 | 8-K | Current Report |
| Apr 27, 2026 | DEF 14A | Other definitive proxy statements |